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Cardiovascular disease is the single most important cause
of morbidity and mortality among chronic kidney disease
(CKD) patients and patients on dialysis [1,2]. Though
controversial, risk for death associated with peritoneal
dialysis (PD) compared with hemodialysis seemed to
be higher in patients with cardiovascular disease at the
start of dialysis than in those without [3]. Apart from
“traditional” cardiovascular risk factors so well known
in the general population, “nontraditional” risk factors,
such as extracellular volume overload, inflammation,
anemia, and abnormal calcium-phosphorus control, have
been found to be important among CKD patients. There
is much evidence of the role of residual renal function
and malnutrition in the progression of atherosclerosis,
vascular calcification and cardiovascular outcomes in PD
patients [4]. Endothelial dysfunction (impaired nitric
oxide synthesis, altered smooth muscle cell proliferation,
reduced angiogenesis, activation of coagulation,
increased cell adhesion to the vascular wall) may prove
to contribute to the high risk for vascular disease in CKD
patients [5]. Also, the accumulation of proinflammatory
cytokines, asymmetric dimethylarginine, homocysteine,
and advanced glycation endproducts in CKD patients is
associated with vascular inflammation and oxidative
stress induction [5].
Apart from the presence of a unique cardiovascular
risk profile in CKD patients, evidence suggests that
the i r  t he rapeu t i c  op t ions  dese rve  spec i a l
considerations. Anemia is detrimental to patients with
congestive heart failure, but as shown in the CREATE
trial on CKD patients, early complete correction of
anemia does not reduce the risk of cardiovascular
events [6]. Also, the observed “reversed phenomenon”
among patients on dialysis, with data mainly from
hemodialysis, suggests that a standard blood pressure
goal among hypertensive subjects may be too low and
not beneficial [7]. Thus, it is apparent that patients on
dialysis may represent a unique population distinct
from the general population.
In the context of renal-cardiovascular disease
interaction, endothelial progenitor cells (EPC), mostly
differentiated from bone marrow-derived hematopoietic
stem cells, have been shown to play an important role in
neovascularization and endothelial repair. Erythropoietin
has been found to help generate an efficient EPC
response, a response already blunted by uremia in CKD
patients [8]. There is also early evidence that renal
replacement therapy can increase the number of EPCs
to levels seen in patients without renal failure [9].
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It has been shown that in hypertensive patients with
renal parenchymal disease, sympathetic activity,
measured by muscle sympathetic nerve activity in the
peroneal nerve, is inappropriately high for the volume
status [10]. There is evidence that sympathetic activity
is associated with mortality and adverse cardiovascular
outcomes in patients with chronic renal failure [11].
The identification of potent genetic determinants of
adverse symptoms in end-stage renal disease may in
turn affect the risk of vascular complications and
outcome in the PD population. A single nucleotide
polymorphism in the interleukin (IL)-6 gene has been
linked with higher plasma IL-6 levels and comorbidity
score in hemodialysis patients [12] and with higher
diastolic blood pressure and left ventricular mass [13].
Also, the angiotensin converting-enzyme insertion/
deletion polymorphism may determine erythropoietin
responsiveness in patients on continuous ambulatory
PD [14]. Polymorphisms of the human vitamin D
receptor have been associated with increased risk of
developing hypercalcemia [15], and the modulation of
nitric oxide activity via the endothelial nitric oxide
synthase polymorphism [16] and a functionally relevant
polymorphism of IL-6 [17] may affect basal peritoneal
permeability. More directly, myocardial remodeling in
heart failure involves altered gene expression of
molecules critical to the integrity of contractile
(contractile proteins and extracellular matrix) and
electrophysiological (calcium handling, ion channels,
and gap junction) functions [18]. This array of
molecular and cellular mechanisms is exciting but still
leaves us with gaps in the knowledge of the relation
between genetic variation and cardiovascular disease
in CKD patients.
In this issue of the Hong Kong Journal of
Nephrology, Szeto et al [19] studied 189 new PD
patients and the `1-adrenergic receptor polymorphism
(389 GlyAArg), which is known to play an important
role in the pathogenesis of hypertension and heart
failure in subjects with normal renal function. They
prospectively followed for the development of
cardiovascular events. After a mean follow up of 30.2
± 17.7 months, there was no significant difference in
the incidence of the composite cardiovascular end point
and patient survival between the GG and GC/CC
genotype groups. The authors concluded that the `1-
adrenergic receptor polymorphism is not related to
cardiovascular disease in PD patients. They also noted
an unexpectedly low prevalence of mutant CC genotype
S.K. Mak
48 Hong Kong J Nephrol • October 2008 • Vol 10 • No 2
in new PD patients and suggested that PD patients may
represent a highly biased population. However, the
authors have emphasized that it is often difficult to
distinguish genuine ventricular failure in PD patients
from fluid overload secondary to ultrafiltration problem
or noncompliance with fluid intake restrictions. It has
been shown that PD patients are volume expanded and
display more severe left ventricular hypertrophy than
hemodialysis patients [20]. During an episode of fluid
overload, ventricular dysfunction, as assessed by
echocardiography, may become apparent. However,
this would resolve when euvolemia is achieved. Thus,
it is essential to evaluate by serial echocardiography
the systolic and diastolic ventricular function for
accurate assessment of subjects in longitudinal studies.
Small et al [21] examined the possible gene-gene
interaction of the _2C and `1-adrenergic receptor
polymorphisms. Homozygosity for _2C (Del 322–325)
and `1 (389Arg) was associated with a substantially
increased risk of heart failure in black, but not in white
subjects. Understanding the role that genes play in the
development of cardiovascular diseases is essential to
allow effective screening to select individuals at risk
of developing the disease, to implementing early
intervention, and to developing gene therapy
approaches in the future. However, allelic variants at
different genes may have either additive or contrasting
effects. The complex nature of cardiovascular disease
implies that, for individual polymorphisms, associations
are likely to be modest.
It is known that most patients who develop end-stage
renal disease are hypertensive already. Over time on
dialysis, many will develop left ventricular hypertrophy
[22], ischemic heart disease, vascular disease, and may
progress to congestive heart failure. Will the start of
dialysis therapy affect  the evolution of the
cardiovascular status of these CKD patients? Will the
optimal blood pressure goal of patients on dialysis
treatment be different from the standard used for our
general population? Many traditional and kidney
disease-specific risk factors have been associated with
cardiovascular disease, and a number of pharmacologic
and nonpharmacologic interventions have been shown
to alter its natural history; such parameters should be
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